Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease - Top-Institutions - MDSpire

Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease

  • By

  • Olga Halle

  • Jan-Niklas Falke

  • Claudia Kessemeier

  • Khatuna Lobjanidze

  • Emily Fuchshuber

  • Sean Brüske

  • Svenja Gaedcke

  • Marina Schumacher

  • Londa Dähne

  • Jonas Knaup

  • Maresa Borghorst

  • Sophia Pallenberg

  • Melanie Albrecht

  • Adan Chari Jirmo

  • Jana Bergmann

  • Michelle Paulsen

  • Danny Jonigk

  • Peter Braubach

  • Anna-Maria Dittrich

  • June 10, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Hannover Medical School
    Hannover Medical School

    Hannover, Lower Saxony

    Key Differentiators

    • Pulmonology

  • #2

    Temple Lung Center
    Temple Lung Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Pulmonology

  • #3

    Hematology and Hemotherapy Center of the University of Campinas
    Hematology and Hemotherapy Center of the University of Campinas

    Campinas, São Paulo

    Key Differentiators

    • Hematology
    • Pulmonology

Original Source(s)

Type 3 innate lymphoid cells dominate the ILC compartment in endstage lung disease

  • by Olga Halle, Jan-Niklas Falke, Claudia Kessemeier, Khatuna Lobjanidze, Emily Fuchshuber, Sean Brüske, Svenja Gaedcke, Marina Schumacher, Londa Dähne, Jonas Knaup, Maresa Borghorst, Sophia Pallenberg, Melanie Albrecht, Adan Chari Jirmo, Jana Bergmann, Michelle Paulsen, Danny Jonigk, Peter Braubach, Anna-Maria Dittrich

  • June 10, 2026

Related Content

AI-Powered Resting 12-Lead Electrocardiogram Algorithm for Predicting Low Peak Oxygen Consumption: Development and Validation Study

Telomerase-mediated immortalization preserves the anti-inflammatory activity of dental pulp stem cell extracellular vesicles

The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial